Draft:RG3487

RG3487 is a selective α7 nicotinic acetylcholine receptor partial agonist and antagonist to serotonin-3 receptors (5HT3). It demonstrated initial efficacy in a proof-of-concept phase I trial in 80 Alzheimer's patients '''but its development was later discontinued following the conclusion of a later phase II trial without published results. ''' A later study evaluating the effects of RG3487 on cognitive deficits associated with schizophrenia failed to find an effect, although post-hoc analysis revealed improvements in patients with high negative PANSS scores.

Pharmacology
RG3487 is a combined a7 nicotinic agonist and 5HT3 antagonist, a trait it shares with tropesitron.